FDA Approves SINEMET — Organon LLC

# FDA Approves Organon's SINEMET (Carbidopa and Levodopa) for Oral Administration Organon LLC's approval of SINEMET, a combination of carbidopa and levodopa, represents a significant advancement in Parkinson's disease treatment, establishing a foundational therapeutic option that is expected to capture substantial market share in the neurological disorders segment. The oral formulation addresses a major clinical need in managing motor symptoms, positioning Organon to strengthen its presence in the neurology market and generate considerable long-term revenue from this blockbuster indication.